×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CDTX – cidara therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CDTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/28
12:37 pm
cdtx
Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights
11/24
08:00 am
cdtx
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
Low
Report
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
11/21
05:30 pm
cdtx
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTX
Low
Report
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTX
11/19
01:02 pm
cdtx
Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025 [Forbes]
Low
Report
Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025 [Forbes]
11/18
09:14 am
cdtx
Cidara Therapeutics (NASDAQ:CDTX) had its "neutral" rating reaffirmed by analysts at Guggenheim.
Low
Report
Cidara Therapeutics (NASDAQ:CDTX) had its "neutral" rating reaffirmed by analysts at Guggenheim.
11/18
02:41 am
cdtx
Is Cidara Therapeutics Fairly Priced After Its 110% Surge and New Clinical Milestones? [Yahoo! Finance]
Low
Report
Is Cidara Therapeutics Fairly Priced After Its 110% Surge and New Clinical Milestones? [Yahoo! Finance]
11/17
12:00 pm
cdtx
Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages RPTX, SEE, CDTX, MRSN Shareholders to Contact the Firm to Discuss Their Rights
11/17
10:23 am
cdtx
Cidara Therapeutics (NASDAQ:CDTX) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating.
Low
Report
Cidara Therapeutics (NASDAQ:CDTX) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/17
04:39 pm
cdtx
Form SCHEDULE 13D/A Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Low
Report
Form SCHEDULE 13D/A Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
11/14
04:50 pm
cdtx
Form SCHEDULE 13G/A Cidara Therapeutics, Filed by: Commodore Capital LP
Low
Report
Form SCHEDULE 13G/A Cidara Therapeutics, Filed by: Commodore Capital LP
11/14
04:43 pm
cdtx
Form SCHEDULE 13G/A Cidara Therapeutics, Filed by: Paradigm Biocapital Advisors LP
Low
Report
Form SCHEDULE 13G/A Cidara Therapeutics, Filed by: Paradigm Biocapital Advisors LP
11/14
04:35 pm
cdtx
Form SCHEDULE 13G/A Cidara Therapeutics, Filed by: BCLS Fund III Investments, LP
Low
Report
Form SCHEDULE 13G/A Cidara Therapeutics, Filed by: BCLS Fund III Investments, LP
11/14
04:30 pm
cdtx
Form SCHEDULE 13G/A Cidara Therapeutics, Filed by: TCG Crossover GP II, LLC
Low
Report
Form SCHEDULE 13G/A Cidara Therapeutics, Filed by: TCG Crossover GP II, LLC
11/14
04:25 pm
cdtx
Form SC14D9C Cidara Therapeutics, Filed by: Cidara Therapeutics, Inc.
Low
Report
Form SC14D9C Cidara Therapeutics, Filed by: Cidara Therapeutics, Inc.
11/14
04:16 pm
cdtx
Form SCHEDULE 13G/A Cidara Therapeutics, Filed by: Point72 Asset Management, L.P.
Low
Report
Form SCHEDULE 13G/A Cidara Therapeutics, Filed by: Point72 Asset Management, L.P.
11/14
08:17 am
cdtx
Form 8-K Cidara Therapeutics, For: Nov 13
Low
Report
Form 8-K Cidara Therapeutics, For: Nov 13
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/3
Cidara Therapeutics and Mundipharma Form Strategic Partnership to Develop and Commercialize Rezafungin
39.9%
1/22 Form 424B5 Cidara Therapeutics, 17.9%
12/26 Cidara Therapeutics Inc (NASDAQ: CDTX) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 10.5%
3/4 Q4/2019 12/31/2019 EPS -0.420 ZacksConsensus -0.280 ActVsEst (0.140) - Miss 10.1%
1/14 Cidara Therapeutics Inc (NASDAQ: CDTX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.4%
6/5 Cidara Therapeutics Inc (NASDAQ: CDTX) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $6.00 price target on the stock. 8.4%
3/23 Form 4 Cidara Therapeutics, For: Mar 19 Filed by: Sandison Taylor 7.7%
6/27 Form 4 Cidara Therapeutics, For: Jun 17 Filed by: Mineo Chrysa 7.0%
8/7 Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference 6.4%
1/6 Form 4 Cidara Therapeutics, For: Jan 03 Filed by: Daruwala Paul 6.4%
1/22 Form 424B5 Cidara Therapeutics, 17.9%
12/26 Cidara Therapeutics Inc (NASDAQ: CDTX) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 10.5%
3/4 Q4/2019 12/31/2019 EPS -0.420 ZacksConsensus -0.280 ActVsEst (0.140) - Miss 10.1%
1/14 Cidara Therapeutics Inc (NASDAQ: CDTX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.4%
6/5 Cidara Therapeutics Inc (NASDAQ: CDTX) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $6.00 price target on the stock. 8.4%
3/23 Form 4 Cidara Therapeutics, For: Mar 19 Filed by: Sandison Taylor 7.7%
6/27 Form 4 Cidara Therapeutics, For: Jun 17 Filed by: Mineo Chrysa 7.0%
8/7 Cidara Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference 6.4%
1/6 Form 4 Cidara Therapeutics, For: Jan 03 Filed by: Daruwala Paul 6.4%
TOP News Decliners
9/3
Thinking about buying stock in Cidara Therapeutics, Canopy Growth, Generac, Lowe's, or Medicines Co?
-22.6%
7/29 Form 8-K Cidara Therapeutics, For: Jul 29 -14.7%
9/3 Cidara Therapeutics Inc (NASDAQ: CDTX) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. -13.5%
1/13 Form 8-K Cidara Therapeutics, For: Jan 13 -10.8%
4/7 Cidara Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference -7.8%
2/21 Form SC 13G Cidara Therapeutics, Filed by: Stonepine Capital Management, LLC -7.4%
1/10 Cidara Therapeutics Announces Proposed Rights Offering -6.7%
7/29 Form 8-K Cidara Therapeutics, For: Jul 29 -6.1%
4/28 Cidara Therapeutics to Participate in Antifungal and COVID-19 Therapeutics Panels at Maxim Group’s Infectious Disease Virtual Conference -6.0%
10/1 Form 4 Cidara Therapeutics, For: Sep 27 Filed by: Oien Jessica -5.9%
7/29 Form 8-K Cidara Therapeutics, For: Jul 29 -14.7%
9/3 Cidara Therapeutics Inc (NASDAQ: CDTX) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. -13.5%
1/13 Form 8-K Cidara Therapeutics, For: Jan 13 -10.8%
4/7 Cidara Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference -7.8%
2/21 Form SC 13G Cidara Therapeutics, Filed by: Stonepine Capital Management, LLC -7.4%
1/10 Cidara Therapeutics Announces Proposed Rights Offering -6.7%
7/29 Form 8-K Cidara Therapeutics, For: Jul 29 -6.1%
4/28 Cidara Therapeutics to Participate in Antifungal and COVID-19 Therapeutics Panels at Maxim Group’s Infectious Disease Virtual Conference -6.0%
10/1 Form 4 Cidara Therapeutics, For: Sep 27 Filed by: Oien Jessica -5.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: